Lurbinectedin is a chemotherapy drug used to treat small cell lung cancer that has spread to other parts of the body and has not responded to other treatments. There is limited information available on how lurbinectedin affects fetal development.

According to the FDA-approved drug label for Lurbinectedin [2], the drug can cause fetal harm when administered to a pregnant woman. Animal studies have shown that Lurbinectedin can cause fetal malformations, and there are no adequate and well-controlled studies in pregnant women. Therefore, Lurbinectedin should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.

The drug's manufacturer, PharmaMar, recommends that women of childbearing potential should use effective contraception during treatment with Lurbinectedin and for at least six months after the last dose of the drug [1]. The drug label also states that lactating women should not breastfeed while receiving Lurbinectedin.

In conclusion, Lurbinectedin can cause fetal harm when administered to pregnant women, according to animal studies. Women of childbearing potential should use effective contraception during treatment with Lurbinectedin and for at least six months after the last dose of the drug. Lactating women should not breastfeed while receiving Lurbinectedin. However, further studies are needed to determine the full extent of the effects of Lurbinectedin on fetal development.

Sources:
[1] https://www.zepzelca.com/
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf